Omnicell Inc (OMCL)

$45.58

-2.92

(-6.02%)▲

Market is closed - opens 7 PM, 27 Sep 2023

Insights on Omnicell Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 290.62M → 298.97M (in $), with an average increase of 2.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -28.40M → 3.45M (in $), with an average increase of 312.0% per quarter

  • Vs TXG

    In the last 1 year, 10x Genomics Inc has given 39.4% return, outperforming this stock by 85.3%

Performance

  • $45.32
    $47.25
    $45.58
    downward going graph

    0.57%

    Downside

    Day's Volatility :4.09%

    Upside

    3.54%

    downward going graph
  • $45.32
    $91.99
    $45.58
    downward going graph

    0.57%

    Downside

    52 Weeks Volatility :50.73%

    Upside

    50.45%

    downward going graph

Returns

PeriodOmnicell IncSector (Health Care)Index (Russel 2000)
3 Months
-34.08%
-0.9%
0.0%
6 Months
-18.95%
1.5%
1.0%
1 Year
-45.89%
7.1%
6.4%
3 Years
-36.39%
25.9%
19.9%

Highlights

Market Capitalization
2.1B
Book Value
$25.74
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.51
PEG Ratio
2.28
Wall Street Target Price
73.43
Profit Margin
-1.88%
Operating Margin TTM
-1.79%
Return On Assets TTM
-0.64%
Return On Equity TTM
-2.06%
Revenue TTM
1.2B
Revenue Per Share TTM
27.58
Quarterly Revenue Growth YOY
-9.8%
Gross Profit TTM
596.7M
EBITDA
36.3M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
-0.62
EPS Estimate Current Year
1.8
EPS Estimate Next Year
2.34
EPS Estimate Current Quarter
0.28
EPS Estimate Next Quarter
0.45

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Omnicell Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 61.1%

Current $45.58
Target $73.43

Company Financials

FY17Y/Y Change
Revenue
716.2M
↑ 3.4%
Net Income
20.6M
↑ 3317.08%
Net Profit Margin
2.88%
↑ 2.79%
FY18Y/Y Change
Revenue
787.3M
↑ 9.93%
Net Income
37.7M
↑ 83.11%
Net Profit Margin
4.79%
↑ 1.91%
FY19Y/Y Change
Revenue
897.0M
↑ 13.94%
Net Income
61.3M
↑ 62.58%
Net Profit Margin
6.84%
↑ 2.05%
FY20Y/Y Change
Revenue
892.2M
↓ 0.54%
Net Income
32.2M
↓ 47.51%
Net Profit Margin
3.61%
↓ 3.23%
FY21Y/Y Change
Revenue
1.1B
↑ 26.88%
Net Income
77.8M
↑ 141.81%
Net Profit Margin
6.88%
↑ 3.27%
FY22Y/Y Change
Revenue
1.3B
↑ 14.48%
Net Income
5.6M
↓ 92.74%
Net Profit Margin
0.44%
↓ 6.44%
Q1 FY22Q/Q Change
Revenue
318.8M
↑ 2.51%
Net Income
8.2M
↓ 41.26%
Net Profit Margin
2.58%
↓ 1.92%
Q2 FY22Q/Q Change
Revenue
331.4M
↑ 3.94%
Net Income
9.1M
↑ 10.42%
Net Profit Margin
2.74%
↑ 0.16%
Q3 FY22Q/Q Change
Revenue
348.1M
↑ 5.03%
Net Income
16.8M
↑ 84.96%
Net Profit Margin
4.82%
↑ 2.08%
Q4 FY22Q/Q Change
Revenue
297.7M
↓ 14.48%
Net Income
-28.4M
↓ 269.36%
Net Profit Margin
-9.54%
↓ 14.36%
Q1 FY23Q/Q Change
Revenue
290.6M
↓ 2.37%
Net Income
-15.0M
↓ 47.2%
Net Profit Margin
-5.16%
↑ 4.38%
Q2 FY23Q/Q Change
Revenue
299.0M
↑ 2.87%
Net Income
3.5M
↓ 123.01%
Net Profit Margin
1.15%
↑ 6.31%
FY17Y/Y Change
Total Assets
980.3M
↑ 4.83%
Total Liabilities
463.1M
↓ 8.02%
FY18Y/Y Change
Total Assets
1.1B
↑ 10.3%
Total Liabilities
401.6M
↓ 13.28%
FY19Y/Y Change
Total Assets
1.2B
↑ 14.76%
Total Liabilities
395.6M
↓ 1.51%
FY20Y/Y Change
Total Assets
1.8B
↑ 47.04%
Total Liabilities
857.0M
↑ 116.66%
FY21Y/Y Change
Total Assets
2.1B
↑ 17.43%
Total Liabilities
995.8M
↑ 16.2%
FY22Y/Y Change
Total Assets
2.2B
↑ 1.74%
Total Liabilities
1.0B
↑ 4.87%
Q1 FY22Q/Q Change
Total Assets
2.1B
↓ 0.93%
Total Liabilities
1.0B
↑ 5.23%
Q2 FY22Q/Q Change
Total Assets
2.1B
↑ 0.42%
Total Liabilities
1.0B
↓ 0.86%
Q3 FY22Q/Q Change
Total Assets
2.2B
↑ 2.26%
Total Liabilities
1.0B
↑ 0.53%
Q4 FY22Q/Q Change
Total Assets
2.2B
↑ 1.43%
Total Liabilities
1.1B
↑ 3.48%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 1.81%
Total Liabilities
1.1B
↑ 2.56%
Q2 FY23Q/Q Change
Total Assets
2.2B
↓ 2.53%
Total Liabilities
1.0B
↓ 7.04%
FY17Y/Y Change
Operating Cash Flow
24.8M
↓ 48.19%
Investing Cash Flow
-35.0M
↓ 89.75%
Financing Cash Flow
-9.9M
↓ 103.72%
FY18Y/Y Change
Operating Cash Flow
104.0M
↑ 318.64%
Investing Cash Flow
-54.4M
↑ 55.41%
Financing Cash Flow
-13.6M
↑ 37.66%
FY19Y/Y Change
Operating Cash Flow
145.0M
↑ 39.48%
Investing Cash Flow
-61.7M
↑ 13.41%
Financing Cash Flow
-23.5M
↑ 72.68%
FY20Y/Y Change
Operating Cash Flow
185.9M
↑ 28.18%
Investing Cash Flow
-279.9M
↑ 353.86%
Financing Cash Flow
456.3M
↓ 2043.31%
FY21Y/Y Change
Operating Cash Flow
231.8M
↑ 24.72%
Investing Cash Flow
-412.5M
↑ 47.39%
Financing Cash Flow
47.4M
↓ 89.62%
FY22Y/Y Change
Operating Cash Flow
77.8M
↓ 66.45%
Investing Cash Flow
-58.7M
↓ 85.78%
Financing Cash Flow
-21.0M
↓ 144.24%
Q1 FY22Q/Q Change
Operating Cash Flow
-16.0M
↓ 126.82%
Investing Cash Flow
-18.7M
↓ 90.26%
Financing Cash Flow
-32.1M
↓ 581.83%
Q2 FY22Q/Q Change
Operating Cash Flow
-9.6M
↓ 40.29%
Investing Cash Flow
-6.8M
↓ 63.61%
Financing Cash Flow
-1.5M
↓ 95.48%
Q3 FY22Q/Q Change
Operating Cash Flow
21.2M
↓ 321.7%
Investing Cash Flow
-15.9M
↑ 132.76%
Financing Cash Flow
9.1M
↓ 723.69%
Q4 FY22Q/Q Change
Operating Cash Flow
82.2M
↑ 287.97%
Investing Cash Flow
-17.3M
↑ 8.73%
Financing Cash Flow
3.6M
↓ 60.67%

Technicals Summary

Sell

Neutral

Buy

Omnicell Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Omnicell Inc
Omnicell Inc
-19.8%
-18.95%
-45.89%
-36.39%
-36.61%
R1 Rcm Inc
R1 Rcm Inc
-10.03%
3.5%
-17.83%
-10.3%
55.68%
10x Genomics Inc
10x Genomics Inc
-13.51%
-17.89%
39.41%
-67.26%
-22.54%
Veeva Systems Inc.
Veeva Systems Inc.
4.73%
12.31%
23.67%
-29.27%
86.9%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-4.47%
-13.32%
9.46%
9.46%
9.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Omnicell Inc
Omnicell Inc
470.14
NA
2.28
1.8
-0.02
-0.01
0.0
25.74
R1 Rcm Inc
R1 Rcm Inc
128.18
NA
0.77
0.06
-0.02
0.02
0.0
6.55
10x Genomics Inc
10x Genomics Inc
NA
NA
NA
-1.69
-0.22
-0.11
0.0
6.76
Veeva Systems Inc.
Veeva Systems Inc.
60.98
60.98
1.27
4.18
0.15
0.05
0.0
25.85
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
19.51
19.51
NA
3.8
0.15
0.06
0.0
15.62
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Omnicell Inc
Omnicell Inc
Buy
$2.1B
-36.61%
470.14
-1.88%
R1 Rcm Inc
R1 Rcm Inc
Buy
$6.6B
55.68%
128.18
-3.09%
10x Genomics Inc
10x Genomics Inc
Buy
$6.3B
-22.54%
NA
-30.31%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.5B
86.9%
60.98
24.2%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$31.5B
9.46%
19.51
9.62%

Institutional Holdings

  • BlackRock Inc

    13.30%

  • Vanguard Group Inc

    9.87%

  • Wellington Management Company LLP

    8.47%

  • State Street Corporation

    3.77%

  • ClearBridge Advisors, LLC

    2.97%

  • Bank of New York Mellon Corp

    2.90%

Company Information

since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice

Organization
Omnicell Inc
Employees
3780
CEO
Mr. Randall A. Lipps
Industry
Technology Services

Discover More

FAQs